> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Generic Drug Trade Group Opposes Inflectra Suit Dismissal
- URL: https://www.fdaweb.com/generic-drug-trade-group-opposes-inflectra-suit-dismissal/
- Published: 2018-01-30T12:00:00.000Z
- Updated: 2026-09-14T23:18:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140637

The Biosimilars Council, a division of the Association for Accessible Medicines (formerly the Generic Pharmaceutical Association), says a Pennsylvania federal court should not grant a motion by Johnson & Johnson and its Janssen Biotech subsidiary to dismiss a suit brought by Pfizer over its biosimilar Inflectra (infliximab), which is trying to compete with Janssen’s Remicade. “This case presents critical issues regarding the degree to which biosimilars, and the still nascent industry focused on affordable biologic medicines, will be allowed to compete on fair terms with higher-priced branded biologic medicines, as Congress intended when it enacted the Biologics Price Competition and Innovation Act,” the council says in its *amicus* [brief](https://www.accessiblemeds.org/sites/default/files/2018-01/AAM-Amicus-Brief-Pfizer-vs-J%26J-1-26-18.pdf?ref=fdaweb.com). “As more biosimilars are approved …. exclusionary tactics such as those used by defendants to prevent Inflectra from competing against defendants’ branded infliximab product Remicade, if upheld, will provide a roadmap for other pharmaceutical companies to stifle biosimilar competition.”

Pfizer contends that the branded companies have leveraged their current patient base by denying rebates to insurers for current Remicade patients unless the insurers agree not to cover Inflectra for new and future patients who might be willing to choose a lower-cost generic.